X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/05/15/2882418/11676/en/Veru-Announces-Steven-B-Heymsfield-M-D-as-the-Principal-Investigator-for-its-Enobosarm-Phase-2b-Clinical-Trial-for-High-Quality-Weight-Loss.html
https://www.globenewswire.com/news-release/2024/05/08/2877612/11676/en/Veru-Reports-Fiscal-2024-Second-Quarter-Financial-Results-and-Progress-of-its-Enobosarm-High-Quality-Weight-Loss-Clinical-Program.html
https://www.globenewswire.com/news-release/2024/04/01/2855433/11676/en/Veru-Announces-Date-of-2024-Annual-Meeting-of-Shareholders.html
https://www.globenewswire.com//news-release/2024/02/06/2824317/11676/en/Veru-Announces-FDA-Clearance-of-IND-Application-to-Initiate-Phase-2b-Clinical-Trial-with-Enobosarm-to-Treat-Muscle-Loss-Associated-with-Weight-Loss-Drugs.html
https://www.globenewswire.com//news-release/2024/01/08/2805447/11676/en/Veru-Submits-IND-Application-to-FDA-for-the-Development-of-Enobosarm-to-Prevent-Muscle-Loss-While-Augmenting-Fat-Loss-in-Combination-with-GLP-1-Drugs-for-Weight-Loss.html
https://www.globenewswire.com//news-release/2023/12/19/2798523/11676/en/Veru-to-Host-Investor-Call-on-January-4th-2024-to-Discuss-Recent-Financing-and-Strategy-to-Prioritize-the-Development-of-Enobosarm-as-a-Combination-Treatment-to-Prevent-Muscle-Loss.html
https://www.globenewswire.com//news-release/2023/10/04/2754580/11676/en/Veru-Reports-Muscle-Data-from-5-Clinical-Studies-of-Enobosarm-that-Support-the-Advancement-of-Enobosarm-in-Combination-with-Weight-Loss-GLP-1-Drugs-Ozempic-Wegovy-or-Mounjaro-to-Op.html
https://www.globenewswire.com//news-release/2023/09/11/2740642/11676/en/Veru-Reports-Clinical-Data-from-the-Discontinued-ARTEST-Study-of-Enobosarm-Novel-Selective-Androgen-Receptor-Targeting-Agonist-in-AR-ER-HER2-Metastatic-Breast-Cancer.html
https://www.globenewswire.com/news-release/2022/02/01/2376723/11676/en/Veru-Enters-into-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Eli-Lilly-and-Company-to-Evaluate-Enobosarm-in-Combination-with-Verzenio-in-Phase-3-ENABLAR-2-Trial.html
https://www.globenewswire.com/news-release/2022/01/10/2364044/11676/en/Veru-Announces-FDA-Grant-of-Fast-Track-Designation-for-Enobosarm-for-the-Treatment-of-AR-ER-HER2-Metastatic-Breast-Cancer.html
https://www.fiercebiotech.com/biotech/gtx-s-enobosarm-flunks-stress-urinary-incontinence-trial
Market Place
Share 
